Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Dexcom (NASDAQ:DXCM) will release first quarter 2026 financial results after market close on April 30, 2026.
Management will host a concurrent conference call and webcast at 4:30 p.m. Eastern Time the same day; the webcast link will be available and archived on the company's investor relations website.
Dexcom (NASDAQ:DXCM) will present clinical and real-world data at ATTD 2026 (March 11-14) showing Dexcom G7 use in non-insulin Type 2 diabetes is associated with improved A1C and weight management. Presentations also report fewer DKA-related hospitalizations in Type 1 diabetes and positive feasibility results for Dexcom Smart Basal. ATTD sessions will detail near-term product features (G7, G7 15 Day, Dexcom ONE+, Stelo, Clarity, next-gen sensor) and rollout of Dexcom Academy HCP education across multiple countries in 2026.
Dexcom (NASDAQ:DXCM) appointed Rick Osterloh to its Board of Directors, effective February 26, 2026. Osterloh brings more than 20 years of technology leadership and currently serves as Senior Vice President, Platforms & Devices at Google, overseeing Android, Pixel, Nest and Fitbit.
This appointment adds product, platform and AI-integrated hardware expertise to the Board to support Dexcom’s long-term product strategy and innovation in glucose biosensing.
Dexcom (NASDAQ:DXCM) will present an update at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026.
The live presentation begins at approximately 1:05 PM EST and will be concurrently webcast; archived video and webcast links will be available at investors.dexcom.com.
Dexcom (Nasdaq: DXCM) reported Q4 2025 revenue of $1.260 billion, up 13% year-over-year, and full-year 2025 revenue of $4.662 billion, up 16%.
GAAP operating income rose to $323.0 million (25.6% margin) in Q4; cash and marketable securities totaled $2.00 billion. Company launched the G7 15 Day CGM, received FDA clearance for Smart Basal, and reiterated 2026 revenue guidance of $5.16–$5.25 billion.
Dexcom (Nasdaq: DXCM) will roll out AI-enhanced Smart Food Logging and a redesigned Daily Insights in the Stelo app nationwide in the coming weeks. The update adds a nutrition database of over 1 million food items, multiple logging methods (text, barcode, photo), and personalized, card-based recommendations to help users track glucose, nutrition, activity, and sleep.
The company says these features build on prior Smart Food Logging and aim to reduce friction in meal tracking while providing evolving, AI-driven coaching; a reimagined Stelo app is planned later this year pending final development and approvals.
Dexcom (NASDAQ:DXCM) will release its fourth quarter and fiscal year 2025 results after market close on Thursday, February 12, 2026. Management will host a conference call and concurrent webcast to review Q4 and FY2025 performance starting at 4:30 p.m. Eastern Time the same day. The webcast link will be available and archived on the company investor relations site at investors.dexcom.com. To join the call by phone, dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and enter confirmation ID 9430114 about five minutes before the start time.
Dexcom (Nasdaq: DXCM) reported preliminary, unaudited Q4 2025 revenue of approximately $1.260 billion, up 13% year-over-year, with U.S. revenue of about $892 million (+11%) and international revenue of about $368 million (+18%). For fiscal 2025, preliminary revenue was approximately $4.662 billion, up 16% year-over-year. The company reiterated 2025 non-GAAP gross profit margin of ~61% and non-GAAP operating margin of 20–21%. For 2026, Dexcom anticipates revenue of $5.16–$5.25 billion (≈11–13% growth) with non-GAAP gross margin of 63–64% and operating margin of 22–23%. Dexcom also noted the initial launch of its G7 15 Day system and continued rollout of Stelo. Audited results and a conference call are scheduled for Feb 12, 2026 at 4:30 p.m. ET.
Dexcom (NASDAQ:DXCM) announced Jake Leach as president and CEO effective Jan. 1, 2026, and outlined 2026 priorities including a reimagined Stelo app with AI-powered personalization and enhanced food logging, expanded integrations, and the pharmacy launch of the Dexcom G7 15 Day continuous glucose monitor, which began shipping to pharmacies in early January 2026. Leach will speak at CES 2026 on Jan. 7 and present at the J.P. Morgan Healthcare Conference on Jan. 12. The release notes prior leadership grew revenue from about $250M to over $4.6B annually under the prior CEO.
Dexcom (NASDAQ:DXCM) launched Dexcom Academy, a personalised learning platform for healthcare professionals to strengthen confidence in continuous glucose monitoring (CGM) and support consistent diabetes care.
The platform is available as a desktop and mobile app in Belgium, Germany, Kingdom of Saudi Arabia, the Netherlands, and Spain, with further EMEA launches planned for 2026. Features include bite-sized modules, certification courses, case-study clinical scenarios, and training on Dexcom G7 and Dexcom ONE+. A 2025 Dexcom survey found 38% of HCPs in surveyed EMEA markets said ongoing education on diabetes technology could help address care challenges.